Association of obesity and inflammatory marker levels on treatment outcome: Results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs

Journal of Clinical Psychiatry

Volumn 76, Issue 12, 2015, Pages 1635-1641

  Shelton, Richard C ^a   Pencina, Michael J ^b   Barrentine, Lori W ^c   Ruiz, Juan A ^c   Fava, Maurizio ^d   Zajecka, John M ^e   Papakostas, George I ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; METHYLFOLATE CALCIUM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 5 METHYLTETRAHYDROFOLIC ACID; GLUTAMIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; TURBIDIMETRY; BLOOD; COMBINATION DRUG THERAPY; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; INFLAMMATION; MIDDLE AGED;

ADULT; BIOMARKERS; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUTAMATES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT (HEALTH CARE); SEROTONIN UPTAKE INHIBITORS;

EID: 84954201718     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.14m09587     Document Type: Article

References (49)

1. Blume J, Douglas SD, Evans DL. Immune suppression and immune activation in depression. Brain Behav Immun. 2011;25(2):221-229.
2. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457.
3. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-186.
4. Lang UE, Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies. Cell Physiol Biochem. 2013;31(6):761-777.
5. Lichtblau N, Schmidt FM, Schumann R, et al. Cytokines as biomarkers in depressive disorder: current standing and prospects. Int Rev Psychiatry. 2013;25(5):592-603.
6. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord. 2012;139(3):230-239.
7. Penninx BW, Milaneschi Y, Lamers F, et al. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11(1):129.
8. Rosenblat JD, Cha DS, Mansur RB, et al. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23-34.
9. Vogelzangs N, Beekman AT, van Reedt Dortland AK, et al. Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology. 2014;39(7):1624-1634.
10. Shelton RC, Miller AH. Eating ourselves to death (and despair): the contribution of adiposity and inflammation to depression. Prog Neurobiol. 2010;91(4):275-299.
11. Ma Y, Chiriboga DE, Pagoto SL, et al. Association between depression and C-Reactive Protein. Cardiol Res Pract. 2010;2011:286509.
12. Vogelzangs N, Kritchevsky SB, Beekman AT, et al. Depressive symptoms and change in abdominal obesity in older persons. Arch Gen Psychiatry. 2008;65(12):1386-1393.
13. Everson-Rose SA, Lewis TT, Karavolos K, et al. Depressive symptoms and increased visceral fat in middle-aged women. Psychosom Med. 2009;71(4):410-416.
14. Esposito K, Giugliano G, Scuderi N, et al. Role of adipokines in the obesityinflammation relationship: the effect of fat removal. Plast Reconstr Surg. 2006;118(4):1048-1057, discussion 1058-1059.
15. Fain JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74:443-477.
16. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne). 2013;4:71.
17. Papakostas GI, Shelton RC, Zajecka JM, et al. l-Methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267-1274.
18. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive l-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014;75(8):855-863.
19. Trivedi MH, Rush AJ, Ibrahim HM, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73-82.
20. Fava M, Evins AE, Dorer DJ, et al. The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom. 2003;72(3):115-127.
21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62.
22. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised Edition. (DHEW Publication No. ADM 76-338). Rockville, MD: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
23. Greene WH. Econometric Analysis. 5th ed. Prentice Hall; 2003.
24. de Wit L, Luppino F, van Straten A, et al. Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res. 2010;178(2):230-235.
25. Faith MS, Butryn M, Wadden TA, et al. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev. 2011;12(5):e438-e453.
26. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229.
27. Vogelzangs N, Kritchevsky SB, Beekman AT, et al; Health ABC Study. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry. 2010;71(4):391-399.
28. Wiltink J, Michal M, Wild PS, et al. Associations between depression and different measures of obesity (BMI, WC, WHtR, WHR). BMC Psychiatry. 2013;13(1):223.
29. Ma J, Xiao L. Obesity and depression in US women: results from the 2005-2006 National Health and Nutritional Examination Survey. Obesity (Silver Spring). 2010;18(2):347-353.
30. Simon GE, Ludman EJ, Linde JA, et al. Association between obesity and depression in middle-aged women. Gen Hosp Psychiatry. 2008;30(1):32-39.
31. McIntyre RS, Konarski JZ, Wilkins K, et al. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51(5):274-280.
32. Kloiber S, Ising M, Reppermund S, et al. Overweight and obesity affect treatment response in major depression. Biol Psychiatry. 2007;62(4):321-326.
33. Oskooilar N, Wilcox CS, Tong ML, et al. Body mass index and response to antidepressants in depressed research subjects. J Clin Psychiatry. 2009;70(11):1609-1610.
34. Chavda N, Kantharia ND, Jaykaran. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. J Pharmacol Pharmacother. 2011;2(1):11-16.
35. Pasco JA, Nicholson GC, Williams LJ, et al. Association of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010;197(5):372-377.
36. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741.
37. Berk M, Williams LJ, Jacka FN, et al. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013;11:200.
38. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-1095.
39. Schneider HJ, Friedrich N, Klotsche J, et al. The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab. 2010;95(4):1777-1785.
40. Capuron L, Su S, Miller AH, et al. Depressive symptoms and metabolic syndrome: is inflammation the underlying link? Biol Psychiatry. 2008;64(10):896-900.
41. Nakamura K, Fuster JJ, Walsh K. Adipokines: a link between obesity and cardiovascular disease. J Cardiol. 2014;63(4):250-259.
42. Despres JP, Cartier A, Cote M, et al. The concept of cardiometabolic risk: bridging the fields of diabetology and cardiology. Ann Med. 2008;40(7):514-523.
43. Brennan AM, Mantzoros CS. Drug Insight: the role of leptin in human physiology and pathophysiology-emerging clinical applications. Nat Clin Pract Endocrinol Metab. 2006;2(6):318-327.
44. Morris AA, Ahmed Y, Stoyanova N, et al. The association between depression and leptin is mediated by adiposity. Psychosom Med. 2012;74(5):483-488.
45. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008;29(24):2959-2971.
46. Madan AK, Tichansky DS, Coday M, et al. Comparison of IL-8, IL-6 and PGE(2) formation by visceral (omental) adipose tissue of obese Caucasian compared to African-American women. Obes Surg. 2006;16(10):1342-1350.
47. Ciortea R, Mihu D, Mihu CM. Association between visceral fat, IL-8 and endometrial cancer. Anticancer Res. 2014;34(1):379-383.
48. Hyland K. Inherited disorders affecting dopamine and serotonin: critical neurotransmitters derived from aromatic amino acids. J Nutr. 2007;137(suppl 1):1568S-1572S, discussion 1573S-1575S.
49. Kitagami T, Yamada K, Miura H, et al. Mechanism of systemically injected interferonalpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 2003;978(1-2):104-114.